Adial Pharmaceuticals, Inc. Investment Income, Interest
Adial Pharmaceuticals, Inc. (ADIL) reported Investment Income, Interest of $58.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-06-30 was $58.00K, a 141.67% increase year-over-year.
- Adial Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-03-31 was $47.06K, a 33.14% increase year-over-year.
- Adial Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-12-31 was $42.61K, a 20.73% decline year-over-year.
- Adial Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-09-30 was $47.86K, a 5.59% decline year-over-year.
- Adial Pharmaceuticals, Inc. investment income, interest for fiscal 2025 was $149.57K, a 16.28% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. investment income, interest for fiscal 2024 was $178.66K, a 156.04% increase from fiscal 2023.
- Adial Pharmaceuticals, Inc. investment income, interest for fiscal 2023 was $69.78K, a 10.17% increase from fiscal 2022.
- Adial Pharmaceuticals, Inc. investment income, interest for fiscal 2022 was $63.34K, a 868.62% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 3 month as first filed | Investment Income, Interest 6 month | Investment Income, Interest 6 month as first filed | Investment Income, Interest 9 month | Investment Income, Interest 9 month as first filed | Investment Income, Interest 12 month | Investment Income, Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $58.00K 10-Q · filed 2026-08-14 | $105.00K 10-Q · filed 2026-08-14 | $147.67K derived: sum of 3 quarters · filed 2026-08-14 | $195.53K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $47.06K 10-Q · filed 2026-05-08 | $89.67K derived: sum of 2 quarters · filed 2026-05-08 | $137.53K derived: sum of 3 quarters · filed 2026-05-08 | $161.53K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $42.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $90.47K derived: sum of 2 quarters · filed 2026-03-05 | $114.47K derived: sum of 3 quarters · filed 2026-08-14 | $149.57K 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $47.86K 10-Q · filed 2025-11-13 | $71.86K derived: sum of 2 quarters · filed 2026-08-14 | $106.95K 10-Q · filed 2025-11-13 | $160.96K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $24.00K 10-Q · filed 2026-08-14 | $23.75K 10-Q · filed 2025-08-13 | $59.00K 10-Q · filed 2026-08-14 | $59.09K 10-Q · filed 2025-08-13 | $113.10K derived: sum of 3 quarters · filed 2026-08-14 | $163.80K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $35.35K 10-Q · filed 2026-05-08 | $89.10K derived: sum of 2 quarters · filed 2026-05-08 | $139.80K derived: sum of 3 quarters · filed 2026-05-08 | $191.20K derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $53.76K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $104.45K derived: sum of 2 quarters · filed 2026-03-05 | $155.86K derived: sum of 3 quarters · filed 2026-03-05 | $178.66K 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $50.69K 10-Q · filed 2025-11-13 | $102.10K derived: sum of 2 quarters · filed 2025-11-13 | $124.90K 10-Q · filed 2025-11-13 | $136.12K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $51.40K 10-Q · filed 2025-08-13 | $74.21K 10-Q · filed 2025-08-13 | $85.43K derived: sum of 3 quarters · filed 2025-08-13 | $95.67K derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $22.80K 10-Q · filed 2025-05-14 | $34.03K derived: sum of 2 quarters · filed 2025-05-14 | $44.26K derived: sum of 3 quarters · filed 2025-05-14 | $63.69K derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $11.22K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $21.46K derived: sum of 2 quarters · filed 2025-03-04 | $40.89K derived: sum of 3 quarters · filed 2025-03-04 | $69.78K 10-K · filed 2025-03-04 | ||||
| 2023-09-30 | $10.24K 10-Q · filed 2024-11-13 | $29.66K derived: sum of 2 quarters · filed 2024-11-13 | $58.55K 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | $19.43K 10-Q · filed 2024-08-13 | $48.32K 10-Q · filed 2024-08-13 | ||||||
| 2022-12-31 | $47.82K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $51.29K derived: sum of 2 quarters · filed 2024-04-01 | $58.22K derived: sum of 3 quarters · filed 2024-04-01 | $63.34K 10-K · filed 2024-04-01 | $63.21K 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $3.47K 10-Q · filed 2023-11-14 | $3.34K 10-Q · filed 2022-11-14 | $10.40K derived: sum of 2 quarters · filed 2023-11-14 | $15.52K 10-Q · filed 2023-11-14 | $15.39K 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $6.93K 10-Q/A · filed 2023-10-30 | $12.04K 10-Q/A · filed 2023-10-30 | ||||||
| 2021-12-31 | $2.20K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $5.06K derived: sum of 2 quarters · filed 2023-03-30 | $6.24K derived: sum of 3 quarters · filed 2023-03-30 | $6.54K 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $2.86K 10-Q · filed 2022-11-14 | $4.04K derived: sum of 2 quarters · filed 2022-11-14 | $4.34K 10-Q · filed 2022-11-14 | $5.69K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $1.18K 10-Q · filed 2022-08-15 | $1.48K 10-Q · filed 2022-08-15 | $2.83K derived: sum of 3 quarters · filed 2022-08-15 | $5.36K derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $295.00 10-Q · filed 2021-05-17 | $1.64K derived: sum of 2 quarters · filed 2022-03-28 | $4.18K derived: sum of 3 quarters · filed 2022-03-28 | $9.36K derived: sum of 4 quarters · filed 2022-03-28 | ||||
| 2020-12-31 | $1.35K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $3.88K derived: sum of 2 quarters · filed 2022-03-28 | $9.06K derived: sum of 3 quarters · filed 2022-03-28 | $32.49K 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $2.53K 10-Q · filed 2021-11-15 | $7.71K derived: sum of 2 quarters · filed 2021-11-15 | $31.15K 10-Q · filed 2021-11-15 | $63.54K derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $5.18K 10-Q · filed 2021-08-12 | $28.61K 10-Q · filed 2021-08-12 | $61.01K derived: sum of 3 quarters · filed 2021-08-12 | $90.87K derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $23.43K 10-Q · filed 2021-05-17 | $55.83K derived: sum of 2 quarters · filed 2021-05-17 | $85.69K derived: sum of 3 quarters · filed 2021-05-17 | $110.29K derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $32.39K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $62.25K derived: sum of 2 quarters · filed 2021-03-22 | $86.86K derived: sum of 3 quarters · filed 2021-03-22 | $95.23K 10-K · filed 2021-03-22 | ||||
| 2019-09-30 | $29.86K 10-Q · filed 2020-11-13 | $54.46K derived: sum of 2 quarters · filed 2020-11-13 | $62.84K 10-Q · filed 2020-11-13 | |||||
| 2019-06-30 | $24.60K 10-Q · filed 2020-08-13 | $32.98K 10-Q · filed 2020-08-13 | ||||||
| 2019-03-31 | $8.38K 10-Q · filed 2020-05-14 | |||||||
| 2018-12-31 | $7.39K 10-K · filed 2020-03-20 | |||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | -$9.00 derived: sum of 2 quarters · filed 2019-02-19 | $29.00 derived: sum of 3 quarters · filed 2019-02-19 | $367.00 10-K · filed 2019-02-19 | ||||
| 2017-09-30 | -$9.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $29.00 derived: sum of 2 quarters · filed 2018-11-14 | $367.00 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $38.00 10-Q · filed 2018-09-10 | $376.00 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |